Cleveland BioLabs, Inc. (NASDAQ:CBLI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 27, 2018, the stockholders of Cleveland BioLabs, Inc. (the “Company”) approved the Cleveland BioLabs, Inc. Equity Incentive Plan (the “Plan”) at the annual meeting of the Company’s stockholders. The Plan, which replaces the Company’s expiring 2008 equity incentive plan, enables the Company to grant equity or cash awards to eligible officers, employees, directors and consultants. The Plan had previously been approved, subject to stockholder approval, by the Company’s board of directors. A description of the material terms of the Plan is contained in the Company’s definitive proxy statement for the Annual Meeting of Stockholders filed with the Securities and Exchange Commission on March 12, 2018, which is incorporated herein by reference. That summary is qualified in its entirety by reference to the text of the Plan, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting of Stockholders on April 27, 2018 (the "2018 Annual Meeting") in Buffalo, New York. The results of matters submitted to a stockholder vote at the 2018 Annual Meeting are as follows:
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Alexander Andryushechkin |
7,222,259 |
72,571 |
3,305,619 |
|
Anna Evdokimova |
7,134,373 |
160,457 |
3,305,619 |
|
Alexey Nechaev |
7,214,775 |
80,055 |
3,305,619 |
|
Ivan Persiyanov |
7,216,426 |
78,404 |
3,305,619 |
|
Randy S. Saluck |
7,226,518 |
68,312 |
3,305,619 |
|
Daniil Talyanskiy |
7,224,709 |
70,121 |
3,305,619 |
|
Lea Verny |
6,917,914 |
376,916 |
3,305,619 |
Proposal 2: Ratification of Meaden & Moore, Ltd. as the independent registered public accounting firm for fiscal year ending December 31, 2018. The selection of Meaden & Moore, Ltd. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018 was ratified with the votes set forth below:
|
For |
Against |
Abstain |
|
10,283,303 |
189,322 |
127,824 |
Proposal 3: Approval of the Cleveland BioLabs, Inc. Equity Incentive Plan. The resolution relating to the approval of the Cleveland BioLabs, Inc. Equity Incentive Plan was approved with the votes set forth below:
|
For |
Against |
Abstain |
Broker Non-Votes |
|
7,153,925 |
125,446 |
15,459 |
3,305,619 |
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit
|
10.1 |
Cleveland BioLabs, Inc. Equity Incentive Plan
|
CLEVELAND BIOLABS INC ExhibitEX-10.1 2 a101.htm EXHIBIT 10.1 Exhibit Exhibit 10.1CLEVELAND BIOLABS,…To view the full exhibit click here
About Cleveland BioLabs, Inc. (NASDAQ:CBLI)
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5.
